scispace - formally typeset
H

H Saito

Researcher at Nagoya University

Publications -  6
Citations -  758

H Saito is an academic researcher from Nagoya University. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 5, co-authored 6 publications receiving 729 citations.

Papers
More filters
Journal ArticleDOI

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

TL;DR: In this paper, the internal tandem duplication of the human Flt3 gene in approximately 20% of acute myeloid leukemia (AML) cases was identified, and the wild-type and the mutant FLt3 genes were transfected into two IL-3-dependent cell lines, 32D and BA/F3 cells.
Journal ArticleDOI

Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.

TL;DR: HDRIs are the potent inducer or enhancer of differentiation in acute myeloid leukemia and regulate transcription in an ordered manner.
Journal ArticleDOI

Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation

TL;DR: An accurate quantitative assessment of residual disease in the autograft has a high predictive value for subsequent relapse and would help to individualize the treatment for each patient after induction or consolidation therapy.
Journal Article

Protein expression and constitutive phosphorylation of hematopoietic transcription factors PU.1 and C/EBP beta in acute myeloid leukemia blasts.

TL;DR: The first insights into both protein expression and phosphorylation of transcription factors in a large-scale study of patients with acute myeloid leukemia (AML) are presented.
Journal ArticleDOI

Gelatin beads as platforms for targeting molecule and anti-Fas antibody: two major properties of cytotoxic T lymphocytes

TL;DR: The findings suggest that antibody-carrying gelatin beads may be the first step toward the development of artificial CTL and can be applied, for example, to artificial dendritic and stroma cells for theDevelopment of novel biotherapeutic approaches.